AcelRx Pharma (ACRX) Commences Dosing in NanoTab Phase 2

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. This study will enroll approximately 100 patients following bunionectomy surgery, randomized into one of three groups; 20 mcg sufentanil NanoTab, 30 mcg sufentanil NanoTab or placebo, administered by healthcare personnel, as needed every hour. The study will evaluate the ability of sufentanil NanoTabs to manage moderate-to-severe acute pain over the first 12 hours following bunionectomy, and correlate the pain response with sufentanil pharmacokinetics. AcelRx is conducting the study with funding provided by a grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Novo Nordisk (NVO) Reports Positive Results from Paradigm 2
• Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
• Alnylam (ALNY) Updates on Preclinical Data for RNAi Program Targeting ALAS-1

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?